logo
Autism Linked to Fourfold Increase in Parkinson's Disease

Autism Linked to Fourfold Increase in Parkinson's Disease

Medscape30-05-2025
Autism spectrum disorder (ASD) is linked to a fourfold increased risk for early-onset Parkinson's disease (PD), results from the largest, population-based cohort study of its kind to date showed.
The findings indicated 'that there can be shared biological drivers behind ASD and Parkinson's disease,' study investigator, Weiyao Yin, MD, PhD, of the Karolinska Institutet in Stockholm, Sweden, said in a release.
'One hypothesis is that the brain's dopamine system is affected in both cases, since the neurotransmitter dopamine plays an important part in social behavior and motion control,' Yin added.
The study was published online on May 27 in JAMA Neurology .
A Plausible Link
Recent research pointed to a plausible biological link between ASD and PD. However, large, longitudinal studies investigating the risk for PD following an ASD diagnosis are scarce, the researchers noted.
'Our study is the first population-based study, to our knowledge, using prospectively collected data, longitudinal design, and life-course approach to strengthen the inference,' they wrote.
To investigate they used national registry data from more than 2 million individuals born in Sweden between 1974 and 1999 and followed them from age 20 years up to the end of 2022. The median age at study exit was 34 years.
Within this cohort, they identified 51,954 individuals with ASD and 2,226,611 individuals without the disorder.
PD, defined as a first-ever diagnosis of PD or other idiopathic or degenerative parkinsonian disorders, was identified in 438 individuals without ASD (0.02%; 1.3 cases per 100,000 person-years) and in 24 individuals with ASD (0.05%; 3.9 cases per 100,000 person-years), corresponding to a relative risk (RR) of 4.43.
Depression and antidepressant use were present in 46.7% of individuals with ASD, and antipsychotic use, which can cause Parkinson-like symptoms, was present in 31.5%.
Adjusting for depression and antipsychotic use reduced but did not eliminate the association between ASD and PD risk (RR, 3.10 and RR, 2.00, respectively).
Independent of ASD diagnosis, a history of depression and exposure to antipsychotics were linked to a significantly higher risk for PD (RR, 2.01 and RR, 6.34, respectively).
Preterm or early-term birth is a known risk factor for ASD, prompting an examination of its potential association with PD. However, no increased risk for PD was found compared with individuals born at full term.
After adjusting for sex, socioeconomic status, and parental mental illness or PD, the investigators found ASD remained consistently associated with an increased risk for PD.
There are potential biological explanations for the link, Yin told Medscape Medical News .
'One hypothesis suggests that the brain's dopamine system is impacted in both conditions, as the neurotransmitter dopamine plays a crucial role in social behavior and motor control,' Yin said.
There may be a genetic correlation between the two conditions, she added noting that the PARK2 gene may be associated between ASD and early-onset PD.
'ASD is a lifelong condition, and more children with autism now progress into middle and older adulthood. Healthcare services need to provide long-term monitoring for individuals with ASD — a vulnerable group with high comorbidity and a high use of psychotropic medications,' Yin said.
Experts Weigh In
The study is clinically relevant 'mainly because it shows that neurodevelopmental conditions, like ASD, may be associated with clinical signs and diagnoses that may manifest at different ages, and we as clinicians should be aware of that,' Christos Ganos, MD, a neurologist at the Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada, who was not involved with the study, told Medscape Medical News .
'Although neurodevelopmental disorders are diagnosed early in life, there is a need to assess for neurological symptoms and signs also later in life, including to monitor the effects of prescribed medications on neuromotor control,' added Ganos, who is the wolf chair in neurodevelopmental psychiatry, and associate professor of neurology at the University of Toronto, Toronto, Ontario, Canada.
However, he urged caution in linking the specific diagnoses of ASD and PD, as there is a more general link between neurodevelopmental disorders and motor dysfunction.
'Neurodevelopmental disorders are very heterogeneous, and the 'ASD' diagnosis encompasses a lot of different disorders and etiologies. Some of these diagnoses/conditions are linked to motor syndromes that are specifically associated with motor slowing but are not PD, although they could resemble some of its features,' he explained.
Strengths of the study include its large sample size and statistical power to provide estimates 'with more meaningful precision than prior studies,' said Connie Marras, MD, PhD, a movement disorders specialist, and professor of neurology at the University of Toronto.
However, she noted that investigators did not include smoking in the models, which 'may result in an overestimation of the association between ASD and PD,' she added. 'Smoking is less common among individuals with ASD and may constitute a confounder. Smoking is also less common in individuals with Parkinson's disease and is considered a protective factor against PD.'
She also questioned whether the results really have clinical implications for monitoring the emergence of parkinsonism in this population.
'Early detection does not have treatment implications currently, particularly since at present we don't have therapies for PD prevention or slowing of progression. Once we do have such treatments, then monitoring would be justified,' she said.
However, the finding 'could have significant clinical and policy-related implications as these individuals age,' Gregory Wallace, PhD, an autism expert and associate professor of speech, language, and hearing sciences at The George Washington University, Washington, DC, who was not part of the study, told Medscape Medical News.
'Given increased rates of autism diagnoses in younger cohorts, if autistic people are at increased risk for developing parkinsonism as they age, the healthcare system and clinicians who provide care for autistic adults need to be prepared,' said Wallace.
Wallace recently published research showing that co-occurring parkinsonism in adults with autism is linked with lower subjective quality of life, more memory problems, lower sleep quality, and greater depression symptoms.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?
Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?

Yahoo

timean hour ago

  • Yahoo

Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?

Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing serious headwinds. After enjoying a strong run fueled by demand for its obesity treatments, the obesity drug pioneer is now under pressure from rising competition, particularly from Eli Lilly's (LLY) weight-loss drugs, as well as trial setbacks for its next-generation therapies. In fact, things took a sharp turn on July 29, when the company cut its full-year sales growth guidance for the second time in just three months and named a new CEO. The market response was swift and brutal, with NVO shares plunging over 21% in a single day. Now, with second-quarter earnings just around the corner on Aug. 6, does Novo Nordisk's recent plunge present a golden buying opportunity, or is it a clear signal to keep your distance? More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! About Novo Nordisk Stock Best known for its blockbuster weight-loss drugs Ozempic and Wegovy, Novo Nordisk is a global healthcare leader with a long-standing focus on chronic disease. Founded in 1923 and headquartered in Denmark, the company has built a strong foundation in diabetes care while expanding its reach into obesity and other severe health conditions. The company commands a market capitalization of about $217.9 billion. While Novo Nordisk has been a trailblazer in the obesity drug market, its stock has hit a rough patch. Softer demand for its blockbuster drugs, combined with intensifying competition in the weight-loss space, has taken a toll on investor sentiment. The stock has tumbled a staggering 66% from its 52-week high of $139.74 reached in August 2024, and it's currently down 44.7% year-to-date (YTD). In stark contrast, the broader S&P 500 Index ($SPX) has managed to notch a gain of approximately 7.1% over the same period, while its rival Eli Lilly has seen only a marginal drop so far this year, highlighting just how far Novo has fallen out of favor with the market. Given its underwhelming price action, Novo Nordisk stock is starting to look like a value play. Currently trading at just 12.5 times forward earnings, it's priced well below the sector median of 16.87x, and dramatically lower than its own five-year average of 30.92x. Novo Nordisk's Q1 Earnings Snapshot In early May, Novo Nordisk posted a solid first-quarter earnings report for fiscal 2025, but the shine was dulled by a cautious outlook. Total revenue climbed 19% year-over-year (YOY) to 78.1 billion Danish kroner, powered by a massive 85% surge in Wegovy sales, which hit 17.4 billion Danish kroner. Ozempic also continued to perform, with sales rising 18% to 32.7 billion Danish kroner. Profits also impressed, with net profit climbing 14% to 29 billion Danish kroner, while operating profit increased 22% to 38.8 billion Danish kroner. But despite these promising numbers, Novo trimmed its full-year sales growth and operating profit growth guidance, citing 'lower-than-planned penetration of branded GLP-1 treatments in the US.' The company pointed to the growing presence of U.S. compounding pharmacies, which have been legally producing copycat versions of Wegovy and Ozempic under an FDA-approved exemption for addressing drug shortages. That growing parallel market has begun to chip away at Novo's momentum. On a more promising note, the company completed its REDEFINE 2 trial during the quarter, with its next-generation drug CagriSema delivering an impressive 15.7% weight loss in patients with obesity or overweight conditions and type 2 diabetes. Novo plans to file for its first regulatory approval in early 2026, potentially marking the next significant chapter in its obesity pipeline. Novo Nordisk Slashes Guidance Again and Names New CEO On July 29, Novo Nordisk held a conference call that left investors rattled, as it unveiled major leadership changes and another sharp downgrade to its 2025 financial outlook. The company slashed its full-year sales growth guidance to 8%-14%, down from the previously expected 13%-21%. Operating profit growth was also revised lower, now projected at 10%-16% compared to May's forecast of 16%-24%. The revised outlook sent a strong signal that Novo is bracing for a more challenging year ahead. A big part of the pressure comes from its obesity blockbuster, Wegovy. In its update, Novo pointed to several headwinds weighing on U.S. sales, including the continued rise of compounded GLP-1 knockoffs, slower-than-expected market expansion, and increasing competition. These challenges have clouded the outlook for one of Novo's key growth drivers, sparking concerns about whether the company can maintain its dominance in the rapidly growing weight-loss market. Adding to the uncertainty, Novo also announced a leadership shake-up. Maziar Mike Doustdar, the current EVP of international operations, will take over as CEO on Aug. 7, succeeding Lars Fruergaard Jørgensen, whose surprise resignation was announced in May. The transition comes at a pivotal moment, with the company under pressure to protect market share and reignite growth amid shifting dynamics in the obesity drug landscape. What Do Analysts Think About Novo Nordisk Stock? Despite all the swirling uncertainty, there's still a hint of optimism in the air. With Novo Nordisk set to unveil its Q2 earnings on Aug. 6 and a new CEO stepping in shortly after, Wall Street hasn't lost faith, with analysts leaning cautiously bullish, giving the stock a consensus rating of 'Moderate Buy' overall. Of the 19 analysts offering recommendations, seven advise a 'Strong Buy,' nine suggest a 'Hold,' one advocates a 'Moderate Sell,' and the remaining two maintain a 'Strong Sell.' NVO's average analyst price target of $71.75 suggests 47% potential upside from current levels. However, the Street-high target of $112 implies that shares can rally as much as 129.5% from current price levels. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on

Thousands face travel chaos after emergency landing shuts runway at Birmingham airport
Thousands face travel chaos after emergency landing shuts runway at Birmingham airport

Yahoo

timean hour ago

  • Yahoo

Thousands face travel chaos after emergency landing shuts runway at Birmingham airport

Flights in and out of Birmingham were suspended for more than five hours on Wednesday after a light aircraft was forced to make an emergency landing. Police, fire and ambulance crews all went to the runway as the emergency developed. Three people on board the aircraft were treated at the scene, one suffering minor injuries, West Midlands Police said. Passengers faced hours of delays, even after the runway reopened, including many in Europe trying to fly back to Birmingham. Airport bosses announced at around 2.40pm on Wednesday that the runway was temporarily closed. It reopened shortly before 8pm. The light aircraft was heading for Belfast International Airport when it developed landing gear problems. Footage and photographs appeared to show a small white turboprop plane, understood to be a Beechcraft B200 Super King Air, lying flat on the airport tarmac. The same type of aircraft was also involved in a crash at London Southend Airport in July, which killed four people. The Air Accidents Investigations Branch (AAIB) said it had started an investigation, with a team including 'inspectors with expertise in aircraft operations, engineering and recorded data' sent to the scene. Airport chiefs apologised for the disruption. Flights originally scheduled to depart as far back as 2.10pm were taking off after the runway re-opened, but others faced delays as late as 12.10am on Thursday, according to Birmingham Airport's website. Woodgate Aviation, the owner of the plane, said: 'The aircraft returned to Birmingham and made an emergency landing and the main under-carriage collapsed on touch-down.' Diana Celella, an interior designer from Sutton Coldfield, was due to return from Lisbon on a Ryanair flight departing at 8.20pm after a holiday, but saw online that the flight was delayed by nearly three hours. She said: 'My husband and I have had a lovely holiday, so it's a real shame to end it with this delay. 'The atmosphere among fellow passengers is mostly resigned - everyone we've spoken to recognises that it's out of Ryanair's control.' West Midlands Ambulance Service said in a statement: 'We were called at 1.45pm to an incident involving a light aircraft at Birmingham Airport. 'Hazardous Area Response Team (Hart) paramedics and three paramedic officers were sent to the scene. 'Upon arrival we found three patients from the aircraft, all of whom were assessed and discharged at the scene.'

Crackdown on cosmetic surgery ‘cowboys' over botched Brazilian butt lifts and Botox
Crackdown on cosmetic surgery ‘cowboys' over botched Brazilian butt lifts and Botox

Yahoo

time2 hours ago

  • Yahoo

Crackdown on cosmetic surgery ‘cowboys' over botched Brazilian butt lifts and Botox

Ministers want to clamp down on 'cowboy' cosmetic procedures including Botox and Brazilian butt lifts after a string of horror incidents which left customers dead or with catastrophic damage. Officials said the industry had been blighted by 'dodgy practitioners and procedures', with some patients 'maimed' during botched treatments. It follows the case of mother-of-five, Alice Webb, who is thought to be the first person to have died following a non-surgical liquid Brazilian butt lift (BBL) procedure at a UK clinic. The Department of Health and Social Care (DHSC) has proposed new restrictions on who can access and provide treatments in a bid to protect people from 'rogue operators' with no medical training who often provide 'invasive' procedures in homes, hotels and pop-up clinics. The move should also reduce the cost imposed upon the NHS to fix botched procedures, DHSC added. Tim Mitchell, president of the Royal College of Surgeons of England, hailed the proposals as an 'important first step forward for patient safety.' Health minister Karin Smyth said: 'The cosmetics industry has been plagued by a Wild West of dodgy practitioners and procedures. 'There are countless horror stories of cosmetic cowboys causing serious, catastrophic damage.' She said the government would take action too 'root out cowboys' and support 'honest and competent practitioners.' 'This isn't about stopping anyone from getting treatments – it's about preventing rogue operators from exploiting people at the expense of their safety and keeping people safe,' Ms Smyth added. 'We're giving them peace of mind and reducing the cost to the NHS of fixing botched procedures.' The government's proposals include: Only allowing healthy workers who are 'suitably qualified' to be able to deliver high-risk procedures such as (BBLs) Ensuring providers are regulated by the health regulator, the Care Quality Commission. Slapping sanctions and finanial penalties on those who break rules on high-risk procedures Ensuring clinics offering Botox and fillers are licensed Introducing age restrictions to prevent children from trying to follow 'dangerous beauty trends on social media' The timeline for the introduction and completion of these measures was not stated. But the DHSC said it will launch a consultation next year seeking views on the range of procedures which should be covered in the new restrictions. Last month, the Chartered Trading Standards Institute warned that fat injections, BBLs, Botox and fillers are being offered by untrained people in places such as public toilets. Before the proposed regulations come into force, the government has urged people seeking cosmetic procedures to ask for the provider's qualifications and insurance, and to be wary of 'suspiciously cheap' offers. Health officials launched an investigation after a number of people had reactions to Botox injections earlier this year. Professor David Sines CBE, the chair and registrar of Joint Council for Cosmetic Practitioners (JCCP), said the move will 'protect the public from untrained and inexperienced operators and it will save the NHS a considerable amount of time and money putting right the harm done through botched procedures.' The statement added the need for the new measures had become increasingly clear in recent years with the 'explosion of high street outlets offering high-risk procedures delivered by people with limited clinical knowledge and training.' He warned this has led to long-term health complications and, in some cases, has led to patient deaths. Mr Mitchell suggested the government must go further on liquid Brazilian Butt Lifts, which the RCS said the procedure should only be performed by a Cosmetic Surgery Board-certified surgeon. The surgeon warned that the procedure needs medical oversight to prevent serious complications and said that while the government's plans will improve the regulation of non-surgical interventions, it must also urgently improve the regulation of surgical procedures. Millie Kendall, chief executive of the British Beauty Council, said: 'Any measures that increase protection for the general public and professionalise the industry will help instil confidence as well as helping to prevent the normalisation of horror stories that have become synonymous with our sector.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store